NASDAQ:SPPI Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.67 -0.01 (-1.47%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.66▼$0.7150-Day Range$0.54▼$1.0752-Week Range$0.32▼$1.57Volume1.70 million shsAverage Volume1.48 million shsMarket Capitalization$136.15 millionP/E RatioN/ADividend YieldN/APrice Target$2.44 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spectrum Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside263.8% Upside$2.44 Price TargetShort InterestHealthy2.36% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.07Based on 22 Articles This WeekInsider TradingSelling Shares$126,073 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.20) to ($0.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector485th out of 1,002 stocksPharmaceutical Preparations Industry229th out of 488 stocks 3.3 Analyst's Opinion Consensus RatingSpectrum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.44, Spectrum Pharmaceuticals has a forecasted upside of 263.8% from its current price of $0.67.Amount of Analyst CoverageSpectrum Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.36% of the outstanding shares of Spectrum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSpectrum Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spectrum Pharmaceuticals has recently increased by 4.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSpectrum Pharmaceuticals does not currently pay a dividend.Dividend GrowthSpectrum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpectrum Pharmaceuticals has received a 74.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Spectrum Pharmaceuticals is -0.75. Previous Next 2.3 News and Social Media Coverage News SentimentSpectrum Pharmaceuticals has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Spectrum Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 21 people have searched for SPPI on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.MarketBeat Follows12 people have added Spectrum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spectrum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,073.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Spectrum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 27.95% of the stock of Spectrum Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($0.20) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spectrum Pharmaceuticals is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spectrum Pharmaceuticals is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpectrum Pharmaceuticals has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spectrum Pharmaceuticals (NASDAQ:SPPI) StockSpectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.Read More Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Stock News HeadlinesMarch 29, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Upgraded to Hold by StockNews.comMarch 29, 2023 | americanbankingnews.comSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasted to Post FY2023 Earnings of ($0.23) Per ShareMarch 29, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 29, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Raised by Jefferies Financial GroupMarch 25, 2023 | finance.yahoo.comEarnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Trimming Their ForecastsMarch 24, 2023 | finance.yahoo.comSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | americanbankingnews.comJefferies Financial Group Weighs in on Spectrum Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:SPPI)March 22, 2023 | finance.yahoo.comQ4 2022 Spectrum Pharmaceuticals Inc Earnings CallMarch 29, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 22, 2023 | finance.yahoo.comSpectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue EstimatesMarch 22, 2023 | businesswire.comSpectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate UpdateMarch 21, 2023 | msn.comEarnings Preview For Spectrum PharmaceuticalsMarch 20, 2023 | americanbankingnews.comInsider Selling: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Insider Sells $12,901.06 in StockMarch 19, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Earns Hold Rating from Analysts at StockNews.comMarch 19, 2023 | americanbankingnews.comThomas J. Riga Sells 18,153 Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) StockMarch 17, 2023 | finance.yahoo.comSpectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate UpdateFebruary 11, 2023 | thestreet.comWhy Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan ApprovalFebruary 8, 2023 | marketwatch.comSpectrum Pharmaceuticals Shares Rise 8% After J-Code for RolvedonFebruary 8, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid ServicesFebruary 3, 2023 | tmcnet.comFinal Deadline Alert: Bronstein, Gewirtz & Grossman, LLC RemindsFebruary 3, 2023 | wsj.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 2, 2023 | wsj.comDEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 1, 2023 | benzinga.comFRIDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 31, 2023 | wsj.comFRIDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2023 | wsj.comBerger Montague PC Files a Securities Fraud Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) With Expanded Class PeriodJanuary 30, 2023 | benzinga.comFRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 27, 2023 | benzinga.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Company Calendar Last Earnings11/10/2021Today3/28/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(702) 835-6300Fax702-260-7405Employees163Year Founded2002Price Target and Rating Average Stock Price Forecast$2.44 High Stock Price Forecast$4.00 Low Stock Price Forecast$0.75 Forecasted Upside/Downside+263.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-771.78% Return on Equity-204.95% Return on Assets-77.76% Debt Debt-to-Equity Ratio0.15 Current Ratio2.37 Quick Ratio2.15 Sales & Book Value Annual Sales$10.11 million Price / Sales13.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book4.47Miscellaneous Outstanding Shares203,210,000Free Float197,719,000Market Cap$136.15 million OptionableOptionable Beta2.26 Social Links Key ExecutivesThomas J. RigaPresident, Chief Executive Officer & DirectorNora E. BrennanChief Financial Officer, Director & Executive VPShanta P. ChawlaVice President-Clinical DevelopmentKeith M. McGahanSecretary, Chief Legal Officer & Executive VPMichael A. GrabowSenior VP-Corporate Strategy & OperationsKey CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKVerastemNASDAQ:VSTMFortress BiotechNASDAQ:FBIOXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsThomas J RigaSold 18,153 sharesTotal: $14,885.46 ($0.82/share)Keith M McgahanSold 15,733 sharesTotal: $12,901.06 ($0.82/share)Thomas J RigaSold 37,009 sharesTotal: $28,496.93 ($0.77/share)Keith M McgahanSold 11,990 sharesTotal: $9,112.40 ($0.76/share)Armistice Capital LLCBought 324,000 shares on 2/15/2023Ownership: 9.035%View All Insider TransactionsView All Institutional Transactions SPPI Stock - Frequently Asked Questions Should I buy or sell Spectrum Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPPI shares. View SPPI analyst ratings or view top-rated stocks. What is Spectrum Pharmaceuticals' stock price forecast for 2023? 4 brokers have issued 12 month target prices for Spectrum Pharmaceuticals' shares. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they expect the company's stock price to reach $2.44 in the next year. This suggests a possible upside of 263.8% from the stock's current price. View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts. How have SPPI shares performed in 2023? Spectrum Pharmaceuticals' stock was trading at $0.3685 at the beginning of 2023. Since then, SPPI stock has increased by 81.8% and is now trading at $0.67. View the best growth stocks for 2023 here. When is Spectrum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our SPPI earnings forecast. How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. During the same quarter last year, the business posted ($0.37) earnings per share. What guidance has Spectrum Pharmaceuticals issued on next quarter's earnings? Spectrum Pharmaceuticals issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.00 million-$10.00 million, compared to the consensus revenue estimate of $3.82 million. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). What is Spectrum Pharmaceuticals' stock symbol? Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI." Who are Spectrum Pharmaceuticals' major shareholders? Spectrum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.03%), Geode Capital Management LLC (0.80%), Morgan Stanley (0.68%), Millennium Management LLC (0.67%), Renaissance Technologies LLC (0.57%) and CM Management LLC (0.36%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton. View institutional ownership trends. How do I buy shares of Spectrum Pharmaceuticals? Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spectrum Pharmaceuticals' stock price today? One share of SPPI stock can currently be purchased for approximately $0.67. How much money does Spectrum Pharmaceuticals make? Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $136.15 million and generates $10.11 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. How many employees does Spectrum Pharmaceuticals have? The company employs 163 workers across the globe. How can I contact Spectrum Pharmaceuticals? Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405. This page (NASDAQ:SPPI) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.